Correction to “Patent Review of Manufacturing Routes to Recently

Addition/Correction pubs.acs.org/OPRD

Correction to “Patent Review of Manufacturing Routes to Recently Approved Oncology Drugs: Ibrutinib, Cobimetinib, and Alectinib” David L. Hughes Cidara Therapeutics, Inc., 6310 Nancy Ridge Dr., Suite 101, San Diego, California 92121, United States

Org. Process Res. Dev. 2016, 20 (11), 1855−1869. DOI: 10.1021/acs.oprd.6b00304 In the original publication, the drawings of alectinib throughout the article omitted the 2,3-double bond in the indole ring. The corrected structure and Schemes are noted herein. Corrected Table of Contents Graphic:

Corrected structure of alectinib (p 1855):

© XXXX American Chemical Society

A

DOI: 10.1021/acs.oprd.6b00423 Org. Process Res. Dev. XXXX, XXX, XXX−XXX

Organic Process Research & Development

Addition/Correction

Corrected Scheme 17. Medicinal Chemistry Route to Alectinib (p 1865):

B

DOI: 10.1021/acs.oprd.6b00423 Org. Process Res. Dev. XXXX, XXX, XXX−XXX

Organic Process Research & Development

Addition/Correction

Corrected Scheme 18. Second Generation Route to Alectinib:

Corrected structure 90 (p 1867):

C

DOI: 10.1021/acs.oprd.6b00423 Org. Process Res. Dev. XXXX, XXX, XXX−XXX